Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 25-34

  Yoneda, Tomoko ^a   Kuboyama, Ayumi ^a   Kato, Kiyoko ^a   Ohgami, Tatsuhiro ^a   Okamoto, Kanako ^a   Saito, Toshiaki ^b   Wake, Norio ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Endometrial cancer; ESR1 PvuII XbaI; MDM2 SNP309; p21 codon 31; TP53 Arg72Pro

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; GENOMIC DNA; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER RISK; CANCER STAGING; CODON; CONTROLLED STUDY; ENDOMETRIUM CANCER; ESR1 GENE; FEMALE; GENE ACTIVITY; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GERM LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MDM2 GENE; ONCOGENE; P21 GENE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84878198730     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2433     Document Type: Article

References (42)

1. Bansal N, Yendluri V and Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16: 8-13, 2009.
2. Prat J, Gallardo A, Cuatrecasas M and Catasus L: Endometrial carcinoma: pathology and genetics. Pathology 39: 72-87, 2007.
3. Deb SP: Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 1: 1009-1016, 2003.
4. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997. (Pubitemid 27220766)
5. Honda R, Tanaka H and Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27, 1997. (Pubitemid 28037193)
6. Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997. (Pubitemid 27220767)
7. Levav-Cohen Y, Haupt S and Haupt Y: Mdm2 in growth signaling and cancer. Growth Factors 23: 183-192, 2005. (Pubitemid 43203049)
8. Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P and Cowan KH: Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1: 71-80, 1995.
9. Sheikh MS, Shao ZM, Hussain A and Fontana JA: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53: 3226-3228, 1993. (Pubitemid 23223285)
10. Ries S, Biederer C, Woods D, et al: Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103: 321-330, 2000.
11. Kato K, Ueoka Y, Hachiya T, Nishida J and Wake N: Contribution of enhanced transcriptional activation by ER to [12Val] K-Ras mediated NIH3T3 cell transformation. Oncogene 15: 3037-3046, 1997. (Pubitemid 28043483)
12. Kato K, Horiuchi S, Takahashi A, et al: Contribution of estrogen receptor α to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway. J Biol Chem 277: 11217-11224, 2002. (Pubitemid 34952884)
13. Suga S, Kato K, Ohgami T, et al: An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol 105: 341-350, 2007. (Pubitemid 46613898)
14. Bond GL, Hu W, Bond EE, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602, 2004. (Pubitemid 39535748)
15. Bond GL, Hirshfield KM, Kirchhoff T, et al: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110, 2006. (Pubitemid 43844932)
16. Campbell IG, Eccles DM and Choong DY: No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240: 195-197, 2006. (Pubitemid 44093819)
17. Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B and Yulug IG: Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 26: 4975-4977, 2006. (Pubitemid 46032145)
18. Krekac D, Brozkova K, Knoflickova D, et al: MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology 74: 84-87, 2008. (Pubitemid 351915014)
19. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
20. el-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993. (Pubitemid 23346378)
21. Roh J, Kim M, Kim J, et al: Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett 165: 59-62, 2001. (Pubitemid 32206658)
22. Roh JW, Kim JW, Park NH, et al: p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 93: 499-505, 2004. (Pubitemid 38507625)
23. Hachiya T, Kuriaki Y, Ueoka Y, Nishida J, Kato K and Wake N: WAF1 genotype and endometrial cancer susceptibility. Gynecol Oncol 72: 187-192, 1999. (Pubitemid 29093773)
24. Walsh CS, Miller CW, Karlan BY and Koeffler HP: Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 104: 660-664, 2007.
25. Terry K, McGrath M, Lee IM, Buring J and De Vivo I: MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 17: 983-986, 2008. (Pubitemid 351536433)
26. Ueda M, Yamamoto M, Nunobiki O, et al: Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell 22: 49-54, 2009.
27. Ueda M, Terai Y, Kanda K, et al: Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 100: 173-178, 2006. (Pubitemid 41815069)
28. Yaich L, Dupont WD, Cavener DR and Parl FF: Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 52: 77-83, 1992.
29. Mizunuma H, Hosoi T, Okano H, et al: Estrogen receptor gene polymorphism and bone mineral density at the lumbar spine of pre- and postmenopausal women. Bone 21: 379-383, 1997. (Pubitemid 27485305)
30. Sun Y, Hildesheim A, Li H, et al: No point mutation but a codon 31ser→arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev 4: 261-267, 1995.
31. Shih CM, Lin PT, Wang HC, Huang WC and Wang YC: Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 91: 9-15, 2000.
32. Issaeva N, Bozko P, Enge M, et al: Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321-1328, 2004. (Pubitemid 40022713)
33. Ashton KA, Proietto A, Otton G, et al: Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol 113: 109-114, 2009.
34. Niwa Y, Hirose K, Matsuo K, et al: Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett 219: 183-190, 2005. (Pubitemid 40269482)
35. Nunobiki O, Ueda M, Yamamoto M, et al: Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell 22: 101-106, 2009.
36. Enomoto T, Fujita M, Inoue M, et al: Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53: 1883-1888, 1993. (Pubitemid 23127119)
37. Wilkening S, Bermejo JL and Hemminki K: MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 28: 2262-2267, 2007. (Pubitemid 350119563)
38. Hu Z, Jin G, Wang L, Chen F, Wang X and Shen H: MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16: 2717-2723, 2007. (Pubitemid 351196328)
39. Wan Y, Wu W, Yin Z, Guan P and Zhou B: MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer 11: 208, 2011.
40. Wo X, Han D, Sun H, et al: MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis. J Genet Genomics 38: 341-350, 2011.
41. Li Y, Zhao H, Sun L, Huang L, Yang Q and Kong B: MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Hum Cell 24: 57-64, 2011.
42. Arva NC, Gopen TR, Talbott KE, et al: A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280: 26776-26787, 2005. (Pubitemid 41040711)